Academician
SİNAN KOCA
DOÇENT
İSTANBUL MEDENİYET ÜNİVERSİTESİ TIP FAKÜLTESİ DAHİLİ TIP BİLİMLERİ BÖLÜMÜ
- Ana Dal Sağlık Bilimleri Temel Alanı
- Yan Dal Tıbbi Onkoloji (İç Hastalıkları)
A quick look at recorded outputs — details below.
- Articles 24
- Projects 0
- Books 5
- Proceedings 58
- Patents 0
- Artistic 0
Scopus (SJR)
Q1
6
Q2
5
Q3
8
Q4
0
WoS (JCR)
Q1
0
Q2
6
Q3
6
Q4
9
TR Index
5
articles
Field+year+type normalized OpenAlex percentiles — not Clarivate ESI / SciVal.
Top 1% articles
0
Top 10% articles
0
Avg percentile
52.8%
Top 1% share
0.0%
Top 10% share
0.0%
Articles
Articles with YÖKSİS and OpenAlex source split; narrow by quartile or TR Index.
Article list
- 2023 Where Should Enzalutamide Be in The Metastatic Castration Resistant Prostate Cancer (mCRPC): A Multi-center Study YÖKSİS TR Index SJR Q3 JCR Q3 OpenAlex 4.4%
- 2023 The Prognostic and Predictive role of DR70 immunoassay in Patients with Advanced (Metastatic) Breast Cancer YÖKSİS TR Index OpenAlex 4.7%
- 2022 Psychological impacts of COVID-19 pandemic in cancer patients on active treatment YÖKSİS SJR Q1 JCR Q2 OpenAlex 79.6%
- 2022 Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group YÖKSİS SJR Q3 JCR Q4 OpenAlex 66.1%
- 2022 The Prognostic and Predictive Value of DR-70 Immunoassay, A Novel Fibrin-Associated Biomarker, in Patients with Advanced Gastrointestinal Cancers YÖKSİS TR Index JCR Q4 OpenAlex 3.5%
- 2021 Efficacy and tolerability of current treatments for hormone-refractory prostate cancer patients with visceral metastases YÖKSİS SJR Q2 JCR Q3 OpenAlex 43.2%
- 2021 Cetuximab-induced rash is associated with overall survival in patients with recurrent/metastatic squamous cell carcinoma of head and neck YÖKSİS SJR Q1 JCR Q3 OpenAlex 11.8%
- 2021 Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer YÖKSİS SJR Q1 JCR Q2
- 2021 Pazopanib for metastatic soft-tissue sarcoma: A multicenter retrospective study YÖKSİS SJR Q3 JCR Q4 OpenAlex 80.7%
- 2021 Modified Glasgow Prognostic Score, Prognostic Nutritional Index and ECOG Performance Score Predicts Survival Better than Sarcopenia, Cachexia and Some Inflammatory Indices in Metastatic Gastric Cancer YÖKSİS SJR Q2 JCR Q3
- 2020 Is eribulin treatment prognostic factor in patients withmetastatic breast cancer treated with this drug? Retrospectiveanalysis of a multicentre study YÖKSİS SJR Q3 JCR Q4
- 2020 Early PSA response to antiandrogen therapy in metastatic castration-resistant prostate carcinoma patients: A predictive marker for progression-free survival? YÖKSİS SJR Q3 JCR Q4
- 2020 Is insulin resistance a predictor for complete response in breast cancer patients who underwent neoadjuvant treatment? YÖKSİS SJR Q2 JCR Q2 OpenAlex 81.9%
- 2020 Response Assessment With Molecular Characterization of Circulating Tumor Cells and Plasma MicroRNA Profiling in Patients With Locally Advanced Breast Cancer During Neoadjuvant Chemotherapy. YÖKSİS SJR Q2 JCR Q3 OpenAlex 59.1%
- 2020 How long should we continue crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? Long-term complete response with crizotinib and review of the literature YÖKSİS SJR Q3 JCR Q4 OpenAlex 88.4%
- 2020 The Relationship Between the Prognostic Nutritional Index and Overall Survival in Elderly Patients with Epithelial Ovarian Cancer YÖKSİS TR Index OpenAlex 69.2%
- 2020 Predictive Values of Preoperative Inflammatory Based Indices in Prognosis of Patients with Resected Rectal Cancer YÖKSİS TR Index OpenAlex 1.4%
- 2019 Assessment of survival and prognostic factors in metastatic colorectal cancer patients treated with first-line bevacizumab based therapy YÖKSİS JCR Q4
- 2017 Comparison of survival with somatostatin analog and chemotherapy and prognostic factors for treatment in 165 advanced neuroendocrine tumor patients with Ki-67 20% or less YÖKSİS SJR Q2 JCR Q3 OpenAlex 63.6%
- 2017 Changes in 18F-FDG-PET/CT tumor metabolism are not consistent with pathologic complete response in hormone-positive breast cancer YÖKSİS SJR Q3 JCR Q4